Do biosimilars improve access to oncology medicines in Asia?
Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access
Some practice-changing results in breast cancer are perceived differently in low-resourced countries
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
How can quantifying the burden of rare cancers in Asia improve patient outcomes?
National cancer control programmes, pharmaceutical company interest and facilitation of clinical trial participation may be stimulated by epidemiological data
Using ex vivo avatars to understand immune reactivation in cancer
Findings call for a change in tumour categorisation, from a cell-of-origin to a tumour microenvironment-associated holistic approach
CHIP clones in solid tumours: therapeutic targets or bystander phenomena?
Ongoing research will help to clarify how CHIP clones may be used to guide therapy for patients with solid tumours
Which immune cell type is it best to target therapeutically in brain tumours?
Research is getting closer to the development of patient-specific tailored treatment approaches for brain tumours, thanks to increased understanding of the tumour microenvironment, including the critical importance of the immune system
New insights into the mechanism of acquired resistance to KRAS G12C inhibitors
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
Study sheds light on lung adenocarcinoma-to-squamous transdifferentiation mechanism
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
Next-generation sequencing of circulating tumour DNA can optimise clinical trial recruitment
Molecular pre-screening identified targetable alterations in patients with unknown genomic drivers
Pathogenic germline variants are more common than ‘incidental’
Tumour-only molecular profiling can spot hereditary cancer syndromes but resources are critical to make the most of this piece of information